|
| miR-192预测晚期肺腺癌PC方案化疗疗效的价值 |
| MiR-192 predicts efficacy of PC chemotherapy forpatients with advanced lung adenocarcinoma |
| 投稿时间：2016-01-27 |
| DOI：10.3969/j.issn.1000-0399.2016.07.004 |
| 中文关键词: 肺腺癌 微小RNA 顺铂 化疗 |
| 英文关键词: Lung cancer MicroRNA Cisplatin Chemotherapy |
| 基金项目: |
|
| 摘要点击次数: 1590 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨晚期肺腺癌患者癌组织中miR-192的表达水平与PC方案化疗疗效的关系。方法 采用qRT-PCR法检测2015年1月至2015年8月安徽医科大学第一附属医院放疗科及化疗科收治的44例晚期肺腺癌患者癌组织中miR-192的表达水平，同时选取相匹配的癌旁组织标本15例作为对照。所有患者接受PC方案化疗，并评价其近期疗效。分析肺腺癌患者癌组织中miR-192的表达水平及癌旁组织中miR-192的表达水平与临床病理特征和PC方案化疗疗效的相关性。结果 癌组织中miR-192的表达水平低于癌旁组织（Z=-2.641，P=0.039），癌组织中miR-192的表达水平与年龄、性别、ECOG评分、癌组织分化和肝转移无相关性。44例患者均可评价疗效，其中无完全缓解病例、14例部分缓解、20例稳定、10例进展，客观缓解率为31.8%，疾病控制率为77.3%，miR-192的表达水平与化疗疗效呈负相关（rs=-0.125，P=0.027）。结论 miR-192水平可以预测晚期肺腺癌患者一线PC方案化疗的近期疗效。 |
| 英文摘要: |
| Objective To investigate the correlation between miR-192 expression in the tumor tissues and the efficacy of first-line PC chemotherapy in patients of advanced lung adenocarcinoma. Methods miR-192 expression was measured by real-time quantitative PCR in the tumor tissues in 44 patients with advanced lung adenocarcinoma and in the adjacent non-tumorous normal tissues from 15 patients. All the enrolled patients received PC treatment,and the chemotherapeutic efficacy was evaluated. miR-192 expression level in tumorous and non-tumorous component and its correlation with clinicopathological characteristics and PC chemotherapy efficacy were evaluated.Results miR-192 expression was lower inside the tumor tissues than in adjacent non-tumorous normal tissues(Z=-2.641,P=0.039)and its level in carcinomatous component was independent of age,sex,ECOG score,tumor grade and liver metastasis. Forty four patients were considered valuable for efficacy. There was CR in zero case,PR in 14 cases,SD in 20 cases,and PD in 10 cases. ORR was 31.8% and DCR was 77.3%. miR-192 expression level was negatively correlated with chemotherapy efficacy(rs=-0.125,P=0.027).Conclusion miR-192 expression in the tumor tissues can predict the efficacy of PC chemotherapy for patients with advanced lung adenocarcinoma. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
